drugset / Trial / NCT04017455
Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)
Phase 2
Active not recruiting
38 enrolled
The Netherlands Cancer Institute
Hoffmann-La Roche · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, patients with resectable rectal cancer will receive radiotherapy, followed by neoadjuvant bevacizumab and atezolizumab
Timeline
- Start
- 2019-10-22
- Primary completion
- 2025-08-31
- Completion
- 2025-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 840 mg | — |
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | — |